Payment overview · 2025
General Payments
$83.20
5 reported records · 5 companies
Healthcare provider profile · identity verified
Jeremiah D Miller, DO
Allopathic & Osteopathic Physicians|Family Medicine · SOPHIA, WV · NPI 1023257599
Verified facts
What the public records show
CMS Open Payments records show Jeremiah D Miller, DO received $83.20 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.32 | 28.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.23 | 20.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.76 | 17.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.30 | 17.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.59 | 16.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.20 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 522 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 106 |
| Lisinopril | Lisinopril | 361 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 355 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 79 |
| Famotidine | Famotidine | 275 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 67 |
| Omeprazole | Omeprazole | 254 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 60 |
| Metformin Hcl | Metformin Hcl | 201 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 197 | 27 |
| Furosemide | Furosemide | 190 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 58 |
| Gabapentin | Gabapentin | 183 | 25 |
| Montelukast Sodium | Montelukast Sodium | 178 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 43 |
| Eliquis | Apixaban | 176 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 54 |
| Losartan Potassium | Losartan Potassium | 135 | 38 |
| Sertraline Hcl | Sertraline Hcl | 130 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 35 |
| Simvastatin | Simvastatin | 112 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 32 |
| Lorazepam | Lorazepam | 102 | 15 |
| Potassium Chloride | Potassium Chloride | 102 | 33 |
| Metformin Hcl Er | Metformin Hcl | 90 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 23 |
| Glimepiride | Glimepiride | 87 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 24 |
| Alendronate Sodium | Alendronate Sodium | 81 | 24 |
| Clonazepam | Clonazepam | 80 | suppressed |
| Ibuprofen | Ibuprofen | 76 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 14 |
| Atenolol | Atenolol | 67 | 17 |
| Allopurinol | Allopurinol | 63 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 16 |
| Trazodone Hcl | Trazodone Hcl | 63 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 16 |
| Amoxicillin | Amoxicillin | 61 | 53 |
| Finasteride | Finasteride | 60 | suppressed |
| Trulicity | Dulaglutide | 60 | 11 |
| Ozempic | Semaglutide | 59 | 18 |
| Naproxen | Naproxen | 58 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 54 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 46 |
| Glipizide | Glipizide | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Buspirone Hcl | Buspirone Hcl | 51 | 11 |
| Methylprednisolone | Methylprednisolone | 51 | 42 |
| Carvedilol | Carvedilol | 50 | 13 |
| Celecoxib | Celecoxib | 49 | 12 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Valsartan | Valsartan | 49 | 14 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 11 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | 11 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Prednisone | Prednisone | 42 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 37 | suppressed |
| Glipizide Er | Glipizide | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 12 |
| Cefdinir | Cefdinir | 22 | 20 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 17 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 18 |
| Mupirocin | Mupirocin | 20 | 15 |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Digoxin | Digoxin | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.20 · 5 records | ABBVIE INC. | FREESTYLE LIBRE 2, Kerendia, Ohtuvayre, Ozempic, QULIPTA, Rybelsus, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error